Phase I study of third-line palliative chemotherapy with low dose paclitaxel for pancreatic cancer

  • Authors:
    • Hidehiro Tajima
    • Mitsuyoshi Okazaki
    • Takahisa Yamaguchi
    • Yoshinao Ohbatake
    • Koichi Okamoto
    • Shinichi Nakanuma
    • Shiro Terai
    • Seisho Sakai
    • Jun Kinoshita
    • Isamu Makino
    • Keishi Nakamura
    • Hironori Hayashi
    • Katsunobu Oyama
    • Masafumi Inokuchi
    • Tomoharu Miyashita
    • Hiroyuki Takamura
    • Itasu Ninomiya
    • Sachio Fushida
    • Tetsuo Ohta
  • View Affiliations

  • Published online on: February 20, 2018     https://doi.org/10.3892/mco.2018.1579
  • Pages: 623-627
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The prognosis of patients with unresectable or recurrent pancreatic cancers is very poor. Prior to development of nab-paclitaxel (PTX) plus gemcitabine (GEM) therapy and FOLFIRINOX therapy, there was no recommended third-line chemotherapy after 5-fluorouracil (5-FU) and GEM-based regimens. The present study conducted a Phase I clinical trial of weekly low-dose PTX as a third-line palliative chemotherapy for patients with pancreatic cancer. PTX was administered on days 1, 8, 15, and 22 of each cycle, repeated twice as follows: Level 1, 40 mg/m2 (n=6); Level 2, 50 mg/m2 (n=4). During the two cycles, three patients developed Grade 3 neutropenia in level 2; thus, the recommended dose was defined as 40 mg/m2. The disease control rate was 40.0% (stable disease, n=4). Median time to treatment failure of the four patients with stable disease was 5.5 months. In conclusion, palliative chemotherapy with low-dose PTX after failure of GEM and 5-FU is well tolerated and safe for unresectable or recurrent pancreatic cancer patients. The unique ID issues by UMIN: 000008148.
View Figures
View References

Related Articles

Journal Cover

April 2018
Volume 8 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Tajima, H., Okazaki, M., Yamaguchi, T., Ohbatake, Y., Okamoto, K., Nakanuma, S. ... Ohta, T. (2018). Phase I study of third-line palliative chemotherapy with low dose paclitaxel for pancreatic cancer. Molecular and Clinical Oncology, 8, 623-627. https://doi.org/10.3892/mco.2018.1579
MLA
Tajima, H., Okazaki, M., Yamaguchi, T., Ohbatake, Y., Okamoto, K., Nakanuma, S., Terai, S., Sakai, S., Kinoshita, J., Makino, I., Nakamura, K., Hayashi, H., Oyama, K., Inokuchi, M., Miyashita, T., Takamura, H., Ninomiya, I., Fushida, S., Ohta, T."Phase I study of third-line palliative chemotherapy with low dose paclitaxel for pancreatic cancer". Molecular and Clinical Oncology 8.4 (2018): 623-627.
Chicago
Tajima, H., Okazaki, M., Yamaguchi, T., Ohbatake, Y., Okamoto, K., Nakanuma, S., Terai, S., Sakai, S., Kinoshita, J., Makino, I., Nakamura, K., Hayashi, H., Oyama, K., Inokuchi, M., Miyashita, T., Takamura, H., Ninomiya, I., Fushida, S., Ohta, T."Phase I study of third-line palliative chemotherapy with low dose paclitaxel for pancreatic cancer". Molecular and Clinical Oncology 8, no. 4 (2018): 623-627. https://doi.org/10.3892/mco.2018.1579